Table 2 Sex and age- adjusted prevalence and prevalence difference of persistent symptoms

From: A population-based serological study of post-COVID syndrome prevalence and risk factors in children and adolescents

Age group (years)

Serological status

Prevalence of symptoms lasting over 12 weeks Percenta,b,c (95%CI)

Prevalence difference of symptoms lasting over 12 weeks Percenta,b,c (95%CI)

Female (n = 528)d

   
 

Negative

4.9 (2.2;7.6)

 
 

Positive

8.3 (4.9;11.6)

 
 

Difference

 

3.4 (−1.1;8.4)

Male (n = 505)d

   
 

Negative

5.0 (2.12;8.0)

 
 

Positive

9.7 (6.4;13.2)

 
 

Difference

 

4.7 (0.2;9.4)

0–5 (n = 160)

   
 

Negative

3.8 (0.0;8.1)

 
 

Positive

8.0 (1.8;14.2)

 
 

Difference

 

4.2 (−4.4;13.3)

6–11 (n = 445)

   
 

Negative

5.3 (2.0;8.6)

 
 

Positive

5.3 (2.6;8.1)

 
 

Difference

 

0.0 (−5.2;5.2)

12–17 (n = 429)

   
 

Negative

5.3 (2.3;8.4)

 
 

Positive

13.6 (9.3;18.1)

 
 

Difference

 

8.3 (3.5;13.5)

All ages (n = 1034)

   
 

Negative

5.0 (3.0;7.1)

 
 

Positive

9.1 (6.7;11.8)

 
 

Difference

 

4.1 (1.1;7.3)

  1. aAdjusted for age and sex, when appropriate.
  2. bA model additionally adjusting for chronic condition, financial situation and parental education yielded similar results.
  3. cUnadjusted estimates are presented in Table S5.
  4. dAs presented in Table 1, one child had no biological sex assigned.
Back to article page